CAS: 15861-36-6; 6-Cyanoindole

上下游产品

CAS号61293-30-9 trans-4-[β-(dim... | CAS号939-79-7 4-甲基-3-硝基氰苯 | CAS号64-19-7 冰醋酸 | CAS号1018038-62-4 1H-indole-6-car... | CAS号85864-09-1 6-氰基吲哚-2-羧酸 | CAS号3468-17-5 (1H-吲哚-6-基)甲胺 | CAS号194163-31-0 6-氰基-1H-吲唑-3-羧酸 | CAS号889676-34-0 1-B°C-6-氰基吲哚 | CAS号1196-70-9 吲哚-6-甲醛 | CAS号1670-82-2 吲哚-6-羧酸 | CAS号882803-60-3 6-氰基-(1h)吲唑-3-甲醛

4-[2-(Dimethylamino)Ethenyl]-3-Nitrobenzonitrile置于palladium On Activated Charcoal 氢气体系中,用 四氢呋喃 用作溶剂,化学反应 0.5H,以9.07 G的收率获得6-氰基吲哚
参考文献:全合成千金菊酸酯.
标题:全合成千金菊酸酯.
摘要:[结构:见正文]已合成了天然存在的大环五肽单链烷酸的甲酯,该甲酯含有一个不寻常的β-取代的α-氨基酸,其色氨酸c-6与亮氨酸的β-碳键相连.关键步骤包括通过thioxo-Oxazolidine中间体形成该氨基酸,以及使用膦酰甘氨酸的horner-Wadsworth-Emmons反应,该膦酰基甘氨酸是由二ho(II)催化的nh插入反应衍生而来的,从而得到脱氢氨基酸和随后的铑( I)催化的不对称氢化以引入修饰的色氨酸残基.
Doi:10.1021/ol060153C

专利信息

专利号:US-12398116-B2
优先权日:2020-09-10
标题:Total synthesis of alectinib
发明人：ZHOU LIHUA
权利人:SUZHOU FUDE ZHAOFENG BIOCHEMICAL TECH CO LTD
摘要:The present invention relates to a process for preparing alectinib or a pharmaceutically acceptable salt thereof. The present invention also relates to intermediate compounds which are useful in such process and to the preparation of such intermediate compounds.

专利号:US-2022363660-A1
优先权日:2020-09-10
标 题 :Total synthesis of alectinib

专利号:CN-115043770-A
优先权日:2022-07-21
标 题:A kind of light-induced synthesis method of indole/azaindole compounds

专利号:WO-2022051983-A1
优先权日:2020-09-10
标题 :Synthesis method of alectinib

专利号:US-8378104-B2
优先权日:2010-02-11
标 题 :7-aminofuropyridine derivatives
发明人：HORNBERGER KEITH R; BERGER DAN M; CHEN XIN; CREW ANDREW P; DONG HANQING; KLEINBERG ANDREW; LI AN-HU; MA LIFU; MULVIHILL MARK J; PANICKER BIJOY; SIU KAM W; STEINIG ARNO G; TARRANT JAMES G; WANG JING; WENG QINGHUA; SANGEM RAJARAM; GUPTA RAMESH C
权利人:OSI PHARMACEUTICALS LLC; HORNBERGER KEITH R; BERGER DAN M; CHEN XIN; CREW ANDREW P; DONG HANQING; KLEINBERG ANDREW; LI AN-HU; MA LIFU; MULVIHILL MARK J; PANICKER BIJOY; SIU KAM W; STEINIG ARNO G; TARRANT JAMES G; WANG JING; WENG QINGHUA; SANGEM RAJARAM; GUPTA RAMESH C
摘要:Compounds of Formula 1, as shown below and defined herein: n n n n n n n n n n n n pharmaceutically acceptable salts thereof, synthesis, intermediates, formulations, and methods of disease treatment therewith, including treatment of cancers, such as tumors driven at least in part by TAK1 or for which an appropriate TAK1 inhibitor is effective. This Abstract is not limiting of the invention.

专利号:CN-112028874-B
优先权日:2020-09-10
标 题 :Synthesis method of eritinib